JPRN-C000000262未知1 期
A phase I/II study of transjugular-transhepatic peritoneo-venous shunting for malignant ascites (JIVROSG-0201) - Transjugular-transhepatic peritoneo-venous shunting for malignant ascites(JIVROSG-0201)
Japan Interventional Radiology in Oncology Study Group (JIVROSG)0 个研究点目标入组 33 人开始时间: 2007年9月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Controllable ascites by standard anti-cancer therapies. 2) Intracavitary administration of anti-cancer agent is scheduled. 3) Controllable ascites by vascular interventions. 4) No symptom due to ascites. 5) Ascites due to malignatnt mesothelioma, mucin-producting tumor, pseudomyxoma. 6) Bloody, chylous or cloudy ascites. 7) Tumor or dilated intestine along the planned route for catheterization. 8) Active infection. 9) Untreated esophageal varices with red-color sign. 10) Active bleeding from upper digestive tract. 11) Post hepatic lobectomy. 12) Cardiac pacemaker. 13) Pregnancy.
研究者
相似试验
尚未招募
不适用
Transjugular intrahepatic portosystemic shunt insertion in hepatic patients on the haemodynamicsPACTR201807337809744ational Liver Institute40
撤回
不适用
The effects of Transjugular Intrahepatic Portosystemic Shunt placement on von Willebrand factor levels in plasma of patients with cirrhosis and portal hypertension.NL-OMON38711niversitair Medisch Centrum Groningen16
招募中
2 期
Phase 1b/2 Study Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced Uveal MelanomaNL-OMON52669eids Universitair Medisch Centrum88
进行中（未招募）
1 期
A study for patients with metastatic uveal melanoma, in which treatment with ipilimumab and nivolumab is combined with hepatic percutaneous perfusioMetastatic uveal melanomaEUCTR2018-004248-49-NLeiden University Medical Center88
已完成
1 期
A phase I/II study of transjugular-transhepatic peritoneo-venous shunting for malignant ascites (JIVROSG-0201)Cancer-related refractory ascitesJPRN-C000000040Japan Interventional Radiology in Oncology Study Group (JIVROSG)33